Document MJ5E9ENqzZw4g7Mden9OQ9mNV

A r .a.ft.6- \k - & i '4 1 C V . T 1 .H VA <w > QIMUWnMt E. I. du Pont de Nemours & C ompany IH U ttH P U lU TT P Wilmington, Delaware 19898 LASTIC PRODUCTS AND RESINS DEPARTM ENT PERSONAL & CONFIDENTIAL CC: R. E. JACKSON R. M. SHEPHERD H. V. BRADLEY E. D. CHAMPNEY J. C. LEITINGER/M. S. EATON - WW W. A. BOWER/R. J. BURGER - WW C. H. FOSHEE - WW J. F. DOUGHTY - WW S. N. BOYD - CD&P B. C. MC KUSICK - CRM), HASKELL B. W. KARRH - ER_______ J. B. ARMITAGE July 18, 1979 TO: J. W. RAINES FROM: L. F. PERCIVAL MINUTES REVIEW OF PRELIMINARY DATA ORGANIC FLUORINE LEVELS IN BLOOD - WASHINGTON WORKS Ref: (1) Letter J. F, Doughty to L. F. Percival, "Data on C-8 Exposure", 7/17/79. (2) Letter Dr. Y. L. Power, M.D. to W. A. Bower, 9/20/78. R. E. Jackson, J. W. Raines and I met with Dr. B. W. Karrh and B. C. McKusick on 7/18 to review the data in References 1 and 2. Meeting with 3M Company - A meeting is planned*with 3M Company (the C-8 manufacturer) on 7/20 to review any new 3M data and results from blood tests run at Chambers Works. It was agreed that B. C. McKusick would report Washington Works' blood data as results of a preliminary study; process data will not be given. McKusick will report to PP&R any findings from the meeting that are significant regarding plans outlined below. Further Blood Sampling at WW - It was agreed that addi tional blood samples should be t a k e n a t W W to meet the following objectives: Check all individuals currently exposed to C-8 in the semiworks (total 8), FEP polykettle operator (total 13) and TFE polykettle operator (total 13). Verify that fluorine in blood levels is due to C-8 exposure rather than from other fluorochemicals. About 4 samples should be taken from "Teflon" Monomer operators (or other personnel from the "Teflon" area) with no potential for C-8 exposure for at least 10 years. *Meeting was arranged May 1979. EID 107194 T H E R E 'S A W ORLD OF T H IN G S W E ARE DOING SO M ETH ING A BO UT 0001S7 RL001775 J. W. RAINES 2 July 18, 1979 Define the biological decay, or buildup, rates of fluorine in blood. W W should develop a program to define decay rates or buildup of fluorine in blood by a careful review of work histories and blood sampling of certain individuals selected from list described below. We should attempt to determine if fluorine in blood levels Increases with increasing lengths (years) of exposure in the jobs with C-8 exposure. We should also sample a few individuals who have left jobs with C-8 exposure for different lengths of time (years). Development of such a program will require careful planning and we would like to review it as soon as practical. CD&P has agreed to continue to analyze samples for PP&R. To help meet the above objectives, lists should.be pre pared of all jobs (including mechanics) and personnel assigned these jobs who would have been routinely potentially exposed to C-8 for a significant period for the past 10 years. Communication with Washington Works1 Employees - Present status should be communicated to affected employees a t a n appro priate time. Public Affairs (C. Perry) is working with information in Reference 1 and 2 to assist in statements to employees. The statements should be cleared with J. W. Raines before being used. Medical Follow-up - Dr. B. Karrh will review data summa rized in Reference 2 directly with Dr. Power and request additional medical analyses as needed. Dordrecht and_ Spruance (Textile Fibers) - We agreed to defer sampling Dordrecht until further samplinghas been completed at WW. McKusick is advising Textile Fibers Department of our present status. Some sampling of affected Spruance employees is indicated. "Teflon" Customers - Any communication will be deferred until plant studies are more complete. Notification of EPA (Section 8(e) - Toxic Substances Control Act) - `The "Substantial Risk" Committee will review next week to decide if a report under 8(e) is required. This will also be discussed with 3M. RL001776 L F P :ldb EID107195 o o o is s U Copies to: t S. N. Boyd, Jr., CD&P, B-16234 Eft)S7S * * V .1 .7 S I B. W. Karrh. M.D.. ERP. N-114D0------ A. A. Wright, Fibre, N-4522 J. W. Raines, PP&R, D-12017 F. J. Marascia/R. D. Richardson/R. E. Raad, CD&I E. 1. du Pont de Nemours & C ompany H. E. Simmons/M. S. Sadler, CR&D, D-6032 IIC O M BIU T1D C. F. Reinhardt/G. L. Kennedy, CR&D, Haskell Wilmington, Delaware 19898 CENTRAI. RESEARCH DEVELOPMENT DEPARTM ENT HASKELL LABORATORY ran tTO X IC O LO G Y AND IN D U STR IA L M ED ICIN E CONFIDENTIAL MEMO TO: F. E. FRENCH, JR. CD&P, B-17249 FROM : B. C. MC KUSICK DISCUSSION OF FLUOROCHEMICALS WITH 3M On July 20, S. N. Boyd, G. L. Kennedy, F. J. Marascia, B. C. McRusick, R. E. Read, and R. D. Richardson of Du Pont met in Chicago with F. D. Griffith, L. C. Krogh, R. A. Prokop, and F. A. Ubel of 3M. Richardson described measurements of organic fluorochemlcals in blood of fluorosurfactant production employees at Chambers Works*. In contrast to experience at 3M, concentrations are normal. A retroactive study of medical records found no adverse health effects. The blood analysis program has been discontinued. Kennedy described Haskell's subacute toxicity studies of CD&P fluorochemicals*. They are consistent with 3M animal data. Prokop of 3M described a gas chromatographic method to determine perfluoroBctanoic a d d (FC-143) in blood, urine, liver, and other biological materials. It can measure as little as 1.5 ppb. A paper has been pre pared (copy attached) that should appear in about six months. Ubel, the 3M medical director, said that no adverse liver effects or other health effects have been found among employees in FC-143 operations. Blood levels of organofluorlne in employees have changed little despite steps to lessen exposure. Blood levels of employees moved to locations outside the fluorochemical area have dropped only slightly, although measurable amounts of organic fluorine is excreted. This was illus trated by data on an employee who had been in the fluorochemical area for 15 years and had the highest blood level of any (Table I). EID107173 (Transparencies attached to copies of French, Simmons, & Reinhardt.) BETTER T H IN G S FO R BETTER LIVING . . . THROUGH CH EM ISTRY 000159 RL001743 MEMO TO: F. E. FRENCH, JR. -2- July 23, 1979 TABLE I ORGANOFLORDOE IN ONE EMPLOYEE Date July 76i Oct 77 Apr 78 May 78 Blood Concentration, ppm RF F- FC-143 39 0.05 40 .03 71 67 53 Urine Cone., ug/24 h r . RF (At this point, he was transferred to another area) June 6, 78 June 13, 78 July 78 Aug 78 Oct 78 Jan 79 Apr 79 66 71 66 55 59 45 47 484 272 160 175 160 220 3M got blood samples from 8 peasants In a Chinese village 30 miles from Canton. The ogranic fluorine was siginficantly lower (0.004-0.017 ppm), than values found in developed countries (e.g., 3M found 0.002-0.13 In 106 members of the general U.S. population). Ubel said that a University of Minnesota professor Is doing an epidemiology study of 4000-5000 employees who have worked at the oldest and biggest 3M plant manufacturing fluorochemlcals. Nothing noteworthy has shown up, but the study has a long way to go. A year ago all employees in fluorochemical manufacture were told the results of the blood study. 3M recently told them about It again. About 60 employees in the fluorochemical area have had blood organic fluorine measured. All who have been found to have elevated organic fluorine blood levels have been Informed of the fact and told that 3M does not know what It means, but that no adverse health effects have been related to It. Hie employees have taken the Information calmly. Griffith, 3M manager of toxicology, reported data on 90-day studies of FC-143 in rats and monkeys (see attachment). The effects were similar to what Du Pont saw with similar materials. Thus, the liver was the main target organ. There was no significant difference in effects between male and female rats, but males retained about 100 times more FC-143! Griffith said he would send me details on this. EIDI07174 000160 RL001744 4 MEMO TO: F. E. FRENCH, JR. -3- July 23, 1979 3M will start a metabolism study of radiolabeled C_F,,C*0_H in rats soon. This may show where FC-143 is being stored in the 5ody. Studies of FC-143 dust on animal skin Indicates it does not penetrate the skin easily. 3M indicated interest in another review in about a year, or whenever one company has interesting results. BCM/bjd RL001745 EID107I75 000161